Browse our 650+ Publications
Latest Publications
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma
Shah N, et al.
Journal of Clinical Oncology
March 2025
Authors and Affiliates
Nirav N. Shah, MD, MS1 ; Alfredo S. Colina, BA2 ; Bryon D. Johnson, PhD1; Aniko Szabo, PhD3; Fateeha Furqan, MD1; Tyce Kearl, MD, PhD1 ;
Dina Schneider, PhD4 ; Marlenny Vargas-Cortes, BS5 ; Jessica L. Schmeling, BS5 ; Michael B. Dwinell, PhD2; Katie Palen, BS1;
Walter Longo, MD1; Peiman Hematti, MD1 ; Anthony E. Zamora, PhD2 ; Parameswaran Hari, MD, MS1 ; Daniel Bucklan, MD6;
Ashley Cunningham, MD7; Mehdi Hamadani, MD1 ; and Timothy S. Fenske, MD1
1BMT & Cellular Therapy Program, Division of Hematology & Oncology,
Medical College of Wisconsin, Milwaukee, WI
2Department of Microbiology & Immunology, Medical College of
Wisconsin, Milwaukee, WI
3Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI
4Lentigen Technology Inc, a Miltenyi Biotec Company, Gaithersburg, MD
5Division of Hematology & Oncology, Department of Medicine, Medical
College of Wisconsin, Milwaukee, WI
6Department of Radiology, Medical College of Wisconsin, Milwaukee,WI
7Department of Pathology, Medical College of Wisconsin, Milwaukee, WI
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Short N, et al.
March 2025
Authors and Affiliates
Nicholas J. Short,1 Ibrahim Aldoss,2 Daniel J. DeAngelo,3 Marina Konopleva,4 Jessica Leonard,5 Aaron C. Logan,6 Jae Park,7 Bijal Shah,8
Wendy Stock,9 and Elias Jabbour1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; 2Department of Hematology and Hematopoietic Cell Transplantation, City of
Hope, Duarte, CA; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Department of Oncology, Montefiore Medical Center, Albert Einstein
College of Medicine, Bronx, NY; 5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR; 6Division of
Hematology, Blood and Marrow Transplantation, and Cellular Therapy, Department of Medicine, University of California San Francisco, San Francisco, CA; 7Memorial Sloan
Kettering Cancer Center, New York, NY; 8Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and 9Department of Medicine Section of Hematology-
Oncology, University of Chicago, Chicago, IL
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Corre J, et al
Blood
March 2025
Authors and Affiliates
Jill Corre,1 Laure Vincent,2 Philippe Moreau,3 Benjamin Hebraud,4 Cyrille Hulin,5 Marie C.
Béné,6 Annemiek Broijl,7 Denis Caillot,8 Michel Delforge,9 Thomas Dejoie,10 Thierry Facon,11
Jérôme Lambert,12 Xavier Leleu,13 Margaret Macro,14 Aurore Perrot,4 Sonja Zweegman,15
Thomas Filleron,16 Bastien Cabarrou,16 Niels W.C.J. van de Donk,15 Sabrina Maheo,1 Winnie
Hua,17 Jianping Wang,18 Maria Krevvata,18 Veronique Vanquickelberghe,19 Carla de Boer,20
Alba Tuozzo,18 Fredrik Borgsten,21 Melissa Rowe,22 Robin Carson,18 Soraya Wuilleme,6 and
Pieter Sonneveld7
1Unité de Genomique du Myélome, IUC- T Oncopole, Toulouse, France;
2Centre Hospitalier Universitaire (CHU) de Montpellier, Montpellier, France;
3Hematology Department, University Hospital Hôtel-Dieu, Nantes, France;
4Université de Toulouse, CHU de Toulouse, Service d’Hématologie, Toulouse, France;
5Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France;
6Hematology Biology, University Hospital Hôtel Dieu, Nantes, France;
7Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, The Netherlands;
8Service d’Hematologie, Institut de Cancérologie de Bourgogne (ICB), Dijon, France;
9University of Leuven, Leuven, Belgium;
Downloaded from http://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2024027620/2362739/blood.2024027620.pdf by guest on 27 March 2025
2
10Biochemistry Laboratory, Nantes University Hospital, Nantes, France;
11University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France;
12Biostatistical Department, Hôpital Saint-Louis, Paris, France;
13University of Poitiers, CHU and Inserm 1313, Poitiers, France;
14Centre Hospitalier Universitaire (CHU) de Caen, Caen, France;
15Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center
Amsterdam, Amsterdam, The Netherlands;
16Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud, IUCT-O, Toulouse,
France;
17Cytel Inc., Waltham, MA, USA;
18Johnson & Johnson, Spring House, PA, USA;
19Johnson & Johnson, Beerse, Belgium;
20Johnson & Johnson, Leiden, The Netherlands;
21Johnson & Johnson, Raritan, NJ, USA;
22Johnson & Johnson, High Wycombe, UK
Antigen-driven expansion of public clonal T-cell populations in inflammatory bowel diseases
Mitchell Pesesky, et al.
Journal of Crohn's and Colitis
March 2025
Authors and Affiliates
Mitchell Pesesky, Ramit Bharanikumar, Lionel Le Bourhis, Hesham ElAbd, Elisa Rosati, Cara L Carty, Namita Singh, Bernd Bokemeyer, Stefan Schreiber, Siegfried Görg, Marco Garcia Noceda, Paidamoyo Chapfuwa, Rachel M Gittelman, Damon May, Jennifer N Dines, Wenyu Zhou, Ian M Kaplan, Thomas M Snyder, Harus Jabran Zahid, Julia Greissl, Haiyin Chen-Harris, Bryan Howie, Andre Franke, Harlan S Robins, Matthieu Allez
Lisocabtagene Maraleucel for Richter’s Transformation—A Case Series
Smith C, et al.
eJHaem
March 2025
Authors and Affiliates
Courtney J. Smith1 Anmol Goyal1 Brian R. Smith1 Dasom Lee2 Alexandria Jensen3 Jonathan Alexander1
Melody Smith1 Matthew Frank1 Saurabh Dahiya1 David Miklos1 Sushma Bharadwaj1
1Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA 2Division of
Hematology, Stanford University School of Medicine, Stanford, California, USA 3Quantitative Sciences Unit, Stanford University School of Medicine, Stanford,
California, USA
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Facon T, et al.
Leukemia
February 2025
Authors and Affiliates
Thierry Facon1, Philippe Moreau 2, Katja Weisel 3, Hartmut Goldschmidt 4, Saad Z. Usmani 5, Ajai Chari6, Torben Plesner7,
Robert Z. Orlowski 8, Nizar Bahlis 9, Supratik Basu 10, Cyrille Hulin 11, Hang Quach 12, Michael O’Dwyer 13,
Aurore Perrot 14, Caroline Jacquet15, Christopher P. Venner16,17, Noopur Raje18, Mourad Tiab19, Margaret Macro20, Laurent Frenzel21,
Xavier Leleu 22, Gordon Cook 23, George Wang24, Huiling Pei25, Maria Krevvata24, Robin Carson24, Fredrik Borgsten26 and
Shaji K. Kumar
1University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France. 2Hematology Department, University Hospital Hôtel-Dieu, Nantes, France. 3Department of Oncology,
Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4GMMG-Study Group at
University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany. 5Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6Icahn School of Medicine at Mount
Sinai, New York, NY, USA. 7Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 8Department of Lymphoma & Myeloma, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA. 9Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada. 10Royal Wolverhampton NHS Trust and University of
Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, UK. 11Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France. 12University of
Melbourne, St Vincent’s Hospital, Melbourne, VIC, Australia. 13Department of Medicine/Haematology, NUI, Galway, Republic of Ireland. 14CHU de Toulouse, IUCT-O, Université de
Toulouse, UPS, Service d’Hématologie, Toulouse, France. 15Department of Hematology, University Hospital, Nancy, France. 16Department of Medical Oncology, Cross Cancer
Institute, University of Alberta, Edmonton, AB, Canada. 17BC Cancer – Vancouver Centre Group, Vancouver, BC, Canada. 18Center for Multiple Myeloma, Massachusetts General
Hospital Cancer Center, Boston, MA, USA. 19CHD Vendée, La Roche sur Yon, France. 20Centre Hospitalier Universitaire (CHU) de Caen, Caen, France. 21Hôpital Necker-Enfants
Malades, Paris, France. 22CHU Poitiers, Hôpital la Milétrie, Poitiers, France. 23Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds,
Leeds, UK. 24Janssen Research & Development, LLC, Spring House, PA, USA. 25Janssen Research & Development, LLC, Titusville, NJ, USA. 26Janssen Research & Development, LLC,
Raritan, NJ, USA. 27Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients with Comparable Rates of Minimal Residual Disease Negativity
Kort J, et al.
Clinical Lymphoma Myeloma & Leukemia
February 2025
Authors and Affiliates
Jeries Korta,b,1, Nikolas Naleidc
, Frank Oleya
, James Ignatz-Hoovera,b, Seunghee
Margeviciusd
, Pingfu Fud
, Ehsan Maleka,b,2, Brenda Coopera,b
a. Department of Hematology and Oncology, University Hospitals Seidman Cancer Center,
Cleveland, OH
b. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
c. Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH
d. Case Western Reserve University, Department of Population and Quantitative Health
Sciences, Cleveland, OH
1. University of Kansas Medical Center, Kansas City, KS
2. Roswell Park Cancer Institute, Buffalo, NY
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Shi Q, et al.
J Clin Oncol
February 2025
Authors and Affiliates
Qian Shi, PhD1 ; Bruno Paiva, PhD2 ; Levi D. Pederson, MS1 ; Natalie Dimier, PhD3; Ela Talpes, PhD4; Thomas J. Prior, PhD5 ;
Alberto Orfao, MD, PhD6 ; Philippe Moreau, MD, PhD7 ; Pieter Sonneveld, MD, PhD8 ; Shaji K. Kumar, MD9 ; Jesse G. Dixon, MS1;
Reshma Patel, PhD10; Blake J. Bartlett, PhD5; Jordan Schecter, MD5; Phillip McCarthy, MD11 ; Dirk Hose, MD12 ; Anja Seckinger, MD12 ;
D’Agostino Mattia, MD13 ; Hartmut Goldschmidt, MD14 ; Stefania Oliva, MD15 ; Roger G. Owen, MD16; Kenneth C. Anderson, MD17 ;
Jes´us San-Miguel, MD, PhD18 ; Brian G.M. Durie, MD19; and Nikhil Munshi, MD17 ; on behalf of the International Independent Team for Endpoint
Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group
1Department of Quantitative Health Sciences, Mayo Clinic, Rochester,
MN
2Department of Hematology and Immunology, University of Navara,
Pamplona, Spain
3Roche Products Limited, St Albans, United Kingdom
4Amgen Inc, San Francisco, CA
5Johnson & Johnson Inc, New Brunswick, NJ
6Department of Medicine, University of Salamanca, Salamanca, Spain
7Hematology Department, University Hospital Hotel-dieu, Nantes,
France
8Department of Hematology, Erasmus MC Cancer Institute, Rotterdam,
the Netherlands
9Division of Hematology, Mayo Clinic, Rochester, MN
10Johnson & Johnson Inc, High Wycombe, United Kingdom
11Roswell Park Cancer Institute, Buffalo, NY
12Department of Hematology and Immunology, Myeloma Center
Brussels & Labor f¨ur Myelomforschung, Vrije Universiteit Brussel (VUB),
Jette, Belgium
13Division of Hematology, Department of Molecular Biotechnology and
Health Sciences, AOU Citt `a della Salute e della Scienza di Torino,
University of Torino, Torino, Italy
14University Hospital Heidelberg, GMMG—Study Group at the University
Hospital Heidelberg, Heidelberg, Germany
15Myeloma Unit, Division of Hematology, University of Torino, Turin,
Italy
16St James Institute, Leeds, United Kingdom
17Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
18Professor of Hematology, Senior Consultant & Strategic Advisor,
Clinica Universidad de Navarra, Pamplona, Spain
19Cedars Sinai Outpatient Cancer Center, Los Angeles, CA
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
Usmani S, et al.
Nature Medicine
February 2025
Authors and Affiliates
Saad Z. Usmani 1 , Thierry Facon2, Vania Hungria3, Nizar J. Bahlis 4, Christopher P. Venner5,6, Marc Braunstein7,
Ludek Pour8, Josep M. Martí9, Supratik Basu 10, Yael C. Cohen 11,12, Morio Matsumoto13, Kenshi Suzuki14, Cyrille Hulin15,
Sebastian Grosicki16, Wojciech Legiec17, Meral Beksac18, Angelo Maiolino 19,20, Hiroyuki Takamatsu21, Aurore Perrot 22,
Mehmet Turgut23, Tahamtan Ahmadi24, Weiping Liu25, Jianping Wang26, Katherine Chastain27, Jessica Vermeulen28,
Maria Krevvata26, Lorena Lopez-Masi27, Jodi Carey26, Melissa Rowe29, Robin Carson26 & Sonja Zweegman30
1Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2University of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France.
3Clínica Médica São Germano, São Paulo, Brazil. 4Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
5Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada. 6BC Cancer—Vancouver Centre, University
of British Columbia, Vancouver, British Columbia, Canada. 7Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. 8University Hospital Brno,
Brno, Czech Republic. 9Hospital Universitario Mútua de Terrassa, Terrassa, Spain. 10Royal Wolverhampton NHS Trust and University of Wolverhampton,
CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK. 11Department of Hematology, Tel Aviv Sourasky (Ichilov)
Medical Center, Tel Aviv, Israel. 12Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. 13Department of Hematology, National
Hospital Organization Shibukawa Medical Center, Gunma, Japan. 14Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
15Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France. 16Department of Hematology and Cancer Prevention, School of
Public Health, Medical University of Silesia, Katowice, Poland. 17Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology
Center of Lublin Land, Lublin, Poland. 18Istinye University, Ankara Liv Hospital, Ankara, Turkey. 19Instituto Americas de Ensino, Pesquisa e Inovação, Rio
de Janeiro, Brazil. 20Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 21Department of Hematology, Kanazawa University Hospital, Kanazawa
University, Kanazawa, Japan. 22CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France. 23Department of
Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey. 24Genmab US, Inc., Plainsboro, NJ, USA. 25Johnson & Johnson, Shanghai,
China. 26Johnson & Johnson, Spring House, PA, USA. 27Johnson & Johnson, Raritan, NJ, USA. 28Johnson & Johnson, Leiden, The Netherlands. 29Johnson &
Johnson, High Wycombe, UK. 30Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam,
The Netherlands.